公开(公告)号：WO2018098270A1

公开(公告)日：2018-05-31

申请号：PCT/US2017/063004

申请日：2017-11-22

申请人： XAVIER UNIVERSITY OF LOUISIANA

发明人： WANG, Guangdi ,  LIU, Jiawang ,  ZHENG, Shilong ,  GUO, Shanchun

IPC分类号： C07F5/02 ,  A61K31/69 ,  A61K31/56 ,  C07C235/56 ,  C07C255/60

CPC分类号： C07F5/025 ,  C07C235/56 ,  C07C255/60 ,  C07J43/003 ,  C07J51/00

摘要： The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.

公开(公告)号：WO2018102261A3

公开(公告)日：2018-06-07

申请号：PCT/US2017/063322

申请日：2017-11-27

申请人： XAVIER UNIVERSITY OF LOUISIANA

发明人： WANG, Guangdi ,  ZHENG, Shilong ,  LIU, Jiawang ,  ZHONG, Qiu ,  GUO, Shanchun

IPC分类号： C07F5/02 ,  A61K31/69

摘要： The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamate s as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.

公开(公告)号：WO2010093615A2

公开(公告)日：2010-08-19

申请号：PCT/US2010/023604

申请日：2010-02-09

申请人： TULANE UNIVERSITY ,  XAVIER UNIVERSITY OF LOUISIANA ,  BECKMAN, Barbara, S. ,  FOROOZESH, Maryam ,  LIU, Jiawang

发明人： BECKMAN, Barbara, S. ,  FOROOZESH, Maryam ,  LIU, Jiawang

IPC分类号： C07C235/02 ,  C07C215/34 ,  A61K31/16 ,  A61K31/133 ,  A61P35/00

CPC分类号： C07C233/60 ,  C07C215/24 ,  C07C233/21 ,  C07C237/06 ,  C07C251/24

摘要： Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compound or a composition comprising a compound are also described.

摘要翻译： 本文公开了化合物及其合成。 还描述了包含化合物的组合物和药物组合物，并且包括还包含脂质体的组合物。 还描述了用于治疗动物中癌症的方法，包括给予化合物或包含化合物的组合物。

公开(公告)号：WO2018102261A2

公开(公告)日：2018-06-07

申请号：PCT/US2017/063322

申请日：2017-11-27

申请人： XAVIER UNIVERSITY OF LOUISIANA

发明人： WANG, Guangdi ,  ZHENG, Shilong ,  LIU, Jiawang ,  ZHONG, Qiu ,  GUO, Shanchun

IPC分类号： C07F5/02 ,  A61K31/69

CPC分类号： C07F5/025

摘要： The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamate s as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.

公开(公告)号：WO2017192991A1

公开(公告)日：2017-11-09

申请号：PCT/US2017/031297

申请日：2017-05-05

申请人： XAVIER UNIVERSITY OF LOUISIANA

发明人： WANG, Guangdi ,  LIU, Jiawang ,  ZHENG, Shilong ,  ZHONG, Qiu ,  GUO, Shanchun

IPC分类号： C07F5/04 ,  A61K31/69

摘要： The present disclosure relates to orally bioavailable selective estrogen receptor down-regulators (SERDs) and the synthesis of the same. Further, the present disclosure teaches the utilization of the orally bioavailable selective estrogen receptor down-regulators (SERDs) in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer.

摘要翻译： 本公开涉及口服生物可利用的选择性雌激素受体下调（SERD）及其合成。 此外，本公开教导了口服生物利用选择性雌激素受体下调（SERD）在治疗增殖性疾病（包括癌症，特别是乳腺癌，特别是ER +乳腺癌）中的应用。